This article is more than 5 years old. Information may no longer be current.

VIDEO: Targeted agents may fill unmet needs in non-small cell lung cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Robert C. Doebele, MD, PhD, associate professor in the division of medical oncology at University of Colorado Anschutz Medical Campus, spoke with HemOnc Today at ASCO Annual Meeting about data related to multiple novel targeted agents.

He discussed results from an investigation of TAK-788 (Millennium Pharmaceuticals/Takeda), a small molecule inhibitor, for patients with EGFR and HER-2 exon 20 mutation-positive non-small cell lung cancer.

“This has been an unmet need for many years,” Doebele told HemOnc Today. “I think it’s very exciting now that we have a few potential drugs that are being developed for this space.”

Doebele also discussed new targeted therapies for RET gene fusion-positive NSCLC, which he also described as an area of unmet need.

Disclosure s : Doebele reports consulting/advisory board roles with AstraZeneca, Bayer, Ignyta and Takeda; licensed biologic materials or patents with Abbott Molecular, Ignyta and Rain Therapeutics; and stock ownership in Rain Therapeutics.